Tilray, Inc. (NASDAQ: TLRY) reported Q3 EPS of ($0.20), versus ($0.02) reported last year. Revenue for the quarter came in at $10 million, versus $5.4 million reported last year.

• Revenue rises 85.8% to $10.0 (C$12.9) million in the third quarter and 78.9% to $27.6 (C$35.5) million year-to-date
• Tilray medical cannabis products available to patients in 12 countries on five continents
• Signed agreements to supply adult-use cannabis to consumers in eight Canadian provinces and territories
• Completed successful $475.0 (C$610.6) million Convertible Senior Notes offering in October

“The cannabis industry remains very robust and we are pleased with our revenue momentum and strategic achievements in the third quarter,” said Brendan Kennedy, President and Chief Executive Officer of Tilray. “We are in the early stages of achieving our growth potential and our team continues to strategically execute on disciplined operational initiatives and investments to support Tilray’s long-term, sustainable growth as the pace of legalization continues to accelerate around the world. Going forward, the demand for our products is strong and we remain committed to expanding our leadership in the global medical and adult-use cannabis markets.”

For earnings history and earnings-related data on Tilray, Inc. (TLRY) click here.